{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:00Z","timestamp":1786982760878,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-025-01158-8","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T09:02:13Z","timestamp":1739610133000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajo M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Alexandra","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Buhleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Philipp","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Gaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bellaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Immisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"K\u00e4mppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brunklaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"10","key":"1158_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"365","author":"P Kwan","year":"2011","unstructured":"Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"1158_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ana.21064","volume":"62","author":"AL Luciano","year":"2007","unstructured":"Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol. 2007;62(4):375\u201381.","journal-title":"Ann Neurol"},{"issue":"11","key":"1158_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(11)70193-4","volume":"10","author":"P Ryvlin","year":"2011","unstructured":"Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10(11):961\u20138.","journal-title":"Lancet Neurol"},{"key":"1158_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17165","author":"C Begley","year":"2022","unstructured":"Begley C, Wagner RG, Abraham A, et al. The global cost of epilepsy: a systematic review and extrapolation. Epilepsia. 2022;63(4):892\u2013903. https:\/\/doi.org\/10.1111\/epi.17165.","journal-title":"Epilepsia"},{"issue":"6","key":"1158_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/epi.17229","volume":"63","author":"LM Willems","year":"2022","unstructured":"Willems LM, Hochbaum M, Z\u00f6llner JP, et al. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia. 2022;63(6):1591\u2013602. https:\/\/doi.org\/10.1111\/epi.17229.","journal-title":"Epilepsia"},{"key":"1158_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109255","volume":"144","author":"LM Willems","year":"2023","unstructured":"Willems LM, Z\u00f6llner JP, Hamann L, et al. Unemployment and early retirement among patients with epilepsy\u2014a study on predictors, resilience factors and occupational reintegration measures. Epilepsy Behav. 2023;144:109255. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109255.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1158_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/epi4.12830","volume":"8","author":"B Schmitz","year":"2023","unstructured":"Schmitz B, Lattanzi S, Vonck K, et al. Cenobamate in refractory epilepsy: overview of treatment options and practical considerations. Epilepsia Open. 2023;8(4):1241\u201355. https:\/\/doi.org\/10.1002\/epi4.12830.","journal-title":"Epilepsia Open."},{"issue":"18","key":"1158_CR8","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1080\/14656566.2020.1803830","volume":"21","author":"A Strzelczyk","year":"2020","unstructured":"Strzelczyk A, Mann C, Willems LM, et al. Cenobamate for the treatment of focal epilepsies. Expert Opin Pharmacother. 2020;21(18):2215\u201323. https:\/\/doi.org\/10.1080\/14656566.2020.1803830.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1158_CR9","doi-asserted-by":"publisher","first-page":"CD014941","DOI":"10.1002\/14651858.CD014941.pub2","volume":"8","author":"F Brigo","year":"2024","unstructured":"Brigo F, Lattanzi S. Cenobamate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2024;8(8):CD014941. https:\/\/doi.org\/10.1002\/14651858.CD014941.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1158_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1158_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108. https:\/\/doi.org\/10.1111\/epi.16525.","journal-title":"Epilepsia"},{"issue":"22","key":"1158_CR12","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000009530.","journal-title":"Neurology"},{"issue":"11","key":"1158_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34(11):1105\u201320. https:\/\/doi.org\/10.1007\/s40263-020-00759-9.","journal-title":"CNS Drugs"},{"issue":"855","key":"1158_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"15","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, et al. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;15(855):175\u201382. https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.007.","journal-title":"Eur J Pharmacol"},{"issue":"879","key":"1158_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"20","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;20(879): 173117. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173117.","journal-title":"Eur J Pharmacol"},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.yebeh.2016.10.025","volume":"66","author":"BJ Steinhoff","year":"2017","unstructured":"Steinhoff BJ, Staack AM, Hillenbrand BC. Randomized controlled antiepileptic drug trials miss almost all patients with ongoing seizures. Epilepsy Behav. 2017;66:45\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2016.10.025.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1158_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/WNL.49.2.333","volume":"49","author":"MC Walker","year":"1997","unstructured":"Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology. 1997;49(2):333\u20137.","journal-title":"Neurology"},{"issue":"7624","key":"1158_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"issue":"3","key":"1158_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/epi.17874","volume":"65","author":"Y Novitskaya","year":"2024","unstructured":"Novitskaya Y, Schutz E, Metternich B, et al. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2024;65(3):630\u201340. https:\/\/doi.org\/10.1111\/epi.17874.","journal-title":"Epilepsia"},{"key":"1158_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18091","author":"R Roberti","year":"2024","unstructured":"Roberti R, Assenza G, Bisulli F, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia. 2024;65(10):2909\u201322. https:\/\/doi.org\/10.1111\/epi.18091.","journal-title":"Epilepsia"},{"key":"1158_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12510-1","author":"S Lauxmann","year":"2024","unstructured":"Lauxmann S, Heuer D, Heckelmann J, et al. Cenobamate: real-world data from a retrospective multicenter study. J Neurol. 2024;271(10):6596\u2013604. https:\/\/doi.org\/10.1007\/s00415-024-12510-1.","journal-title":"J Neurol"},{"issue":"4","key":"1158_CR22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/epi4.12992","volume":"9","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Georgiou D, Intravooth T. The cenobamate KORK study\u2014a prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam. Epilepsia Open. 2024;9(4):1502\u201314. https:\/\/doi.org\/10.1002\/epi4.12992.","journal-title":"Epilepsia Open."},{"issue":"9","key":"1158_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","volume":"38","author":"Y Winter","year":"2024","unstructured":"Winter Y, Abou Dargham R, Patino Tobon S, et al. Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study. CNS Drugs. 2024;38(9):733\u201342. https:\/\/doi.org\/10.1007\/s40263-024-01109-9.","journal-title":"CNS Drugs"},{"key":"1158_CR24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/epi.12284","volume":"54","author":"J Novy","year":"2013","unstructured":"Novy J, Bartolini E, Bell GS, et al. Long term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsia. 2013;54:74.","journal-title":"Epilepsia"},{"issue":"7","key":"1158_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","volume":"21","author":"L Flores","year":"2012","unstructured":"Flores L, Kemp S, Colbeck K, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure Eur J Epilepsy. 2012;21(7):512\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2012.05.005.","journal-title":"Seizure Eur J Epilepsy."},{"issue":"9566","key":"1158_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(07)60460-7.","journal-title":"Lancet"},{"issue":"1\u20132","key":"1158_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.eplepsyres.2011.04.012","volume":"96","author":"CB Catarino","year":"2011","unstructured":"Catarino CB, Bartolini E, Bell GS, et al. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Res. 2011;96(1\u20132):39\u201344. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.04.012.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1158_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1059-1311(02)00258-3","volume":"12","author":"T Betts","year":"2003","unstructured":"Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic\u2014a one year follow up study. Seizure. 2003;12(3):136\u201340.","journal-title":"Seizure."},{"issue":"12","key":"1158_CR29","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/epi.17087","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Zaveta C, von Podewils F, et al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia. 2021;62(12):2994\u20133004. https:\/\/doi.org\/10.1111\/epi.17087.","journal-title":"Epilepsia"},{"issue":"3","key":"1158_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/17512433.2018.1421066","volume":"11","author":"LM Willems","year":"2018","unstructured":"Willems LM, Z\u00f6llner JP, Paule E, et al. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence. Expert Rev Clin Pharmacol. 2018;11(3):309\u201324. https:\/\/doi.org\/10.1080\/17512433.2018.1421066.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1158_CR31","doi-asserted-by":"publisher","first-page":"1120150","DOI":"10.3389\/fneur.2023.1120150","volume":"14","author":"C Liguori","year":"2023","unstructured":"Liguori C, Santamarina E, Strzelczyk A, et al. Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: evidence from the PERMIT study. Front Neurol. 2023;14:1120150. https:\/\/doi.org\/10.3389\/fneur.2023.1120150.","journal-title":"Front Neurol"},{"issue":"9","key":"1158_CR32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","volume":"37","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Laloyaux C, D\u2019Souza W, et al. Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records. CNS Drugs. 2023;37(9):819\u201335. https:\/\/doi.org\/10.1007\/s40263-023-01033-4.","journal-title":"CNS Drugs"},{"key":"1158_CR33","doi-asserted-by":"publisher","unstructured":"Strzelczyk A, Maschio M, Pensel MC, et al. Perampanel for treatment of people with a range of epilepsy aetiologies in clinical practice: evidence from the PERMIT extension study. Neurology and Therapy 2024;13(3):825\u201355. https:\/\/doi.org\/10.1007\/s40120-024-00618-5.","DOI":"10.1007\/s40120-024-00618-5"},{"key":"1158_CR34","doi-asserted-by":"publisher","unstructured":"Szaflarski JP, Besson H, D\u2019Souza W, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol. 2024;271(6):3169\u201385. https:\/\/doi.org\/10.1007\/s00415-024-12253-z.","DOI":"10.1007\/s00415-024-12253-z"},{"issue":"2","key":"1158_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199\u2013218. https:\/\/doi.org\/10.1007\/s40265-021-01661-4.","journal-title":"Drugs"},{"issue":"6","key":"1158_CR36","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/epi4.12927","volume":"9","author":"F Pigliasco","year":"2024","unstructured":"Pigliasco F, Cafaro A, Barco S, et al. A VAMS-based LC-MS\/MS method for precise cenobamate quantification in epilepsy (patients). Epilepsia Open. 2024;9(6):2144\u201353. https:\/\/doi.org\/10.1002\/epi4.12927.","journal-title":"Epilepsia Open."},{"key":"1158_CR37","doi-asserted-by":"publisher","unstructured":"Siebenbrodt K, Willems LM, von Podewils F, et al. Determinants of quality of life in adults with epilepsy: a multicenter cross-sectional study from Germany. Neurol Res Pract. 2023;5(1):41.  https:\/\/doi.org\/10.1186\/s42466-023-00265-5.","DOI":"10.1186\/s42466-023-00265-5"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01158-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01158-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01158-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:58:19Z","timestamp":1740394699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01158-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01158-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"8 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. There is no funding to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. Strzelczyk has received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals,\u00a0Longboard, Neuraxpharm, Takeda, UCB Pharma and UNEEG Medical. F. von Podewils received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, UCB Pharma, Nutricia Milupa GmbH, Neuraxpharm and Bial. H.M. Hamer has served on the scientific advisory board of Angelini, UniQure, Eisai, GW\/Jazz and UCB Pharma. He served on the speakers\u2019 bureau of or received unrestricted grants from Angelini, Ad-Tech, Alnylam, Bracco, Desitin, Eisai, Jazz, LivaNova, Nihon Kohden, Pfizer and UCB Pharma. S. Knake received speakers\u2019 honoraria from Bial, Destin Arzneimittel, Eisai, Jazz Pharma, Merck Serono and UCB. F. Rosenow has received personal fees from Angelini Pharma, Desitin Arzneimittel, Eisai GmbH, Jazz Pharma, Roche Pharma, Stoke Therapeutics and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse and the European Union. K.A. Klotz received speakers\u2019 honoraria from Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals and UCB Pharma. G. Kurlemann received speakers\u2019 honoraria from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB Pharma, Neuraxpharm, Stada Arzneimittel, Precisis GmbH and Alexion Pharmaceuticals. N. Melzer has received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmith Kline, Teva, Novartis Pharma, Bayer Healthcare, Genzyme, Alexion Pharmaceuticals, Fresenius Medical Care, Diamed, UCB Pharma, AngeliniPharma, Bial and Sanofi-Aventis; has received royalties for consulting from UCB Pharma, Alexion Pharmaceuticals and Sanofi-Aventis; and has received financial research support from Euroimmun, Fresenius Medical Care, Diamed, Alexion Pharmaceuticals and Novartis Pharma. C. Mann reports speakers\u2019 honoraria and travel support from UCB, outside of the submitted work. C.M. was supported by the Emmy Klieneberger-Nobel grant from the medical faculty of the Goethe University Frankfurt for female scientists. J.P. Z\u00f6llner has received speakers\u2019 honoraria and travel support from Danone and Desitin Arzneimittel. B. Gaida has received speakers\u2019 honoraria from UCB-Pharma. I. Immisch received personal fees from Jazz Pharmaceuticals, Precisis and Angelini Pharma. L. K\u00e4mppi reports speakers\u2019 honoraria from UCB, Angelini Pharma and Sobi; congress\/travel support from UCB and Angelini Pharma; and personal grants from the Academy of Finland, Finnish Cultural Foundation and HUS Neurocenter. A. Brunklaus has received honoraria for presenting at educational events, advisory boards and consultancy work for Biocodex, Encoded Therapeutics, Jazz\/GW Pharma, Servier, Stoke Therapeutics and UCB\/Zogenix. S. Schubert-Bast has received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Marinus, Takeda and UCB Pharma. E. Buhleier, L.M. Willems, J. Cuny and D. Bellaire do not report any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics committee approval was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was waived due to the retrospective nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.S., F.R. and S.S.B. developed the idea for this study. A.S., F.v.P., H.M.H., S.K., F.R., K.A.K., G.K., N.M., E.B., C.M., L.M.W., J.P.Z., B.G., J.C., D.B., I.I. and S.S.B. participated in the recruitment of patients and data collection. A.S. supervised the study. A.S. and S.S.B. conceived the paper and performed the statistical analysis. A.S., E.B. and L.M.W. created the charts and figures. A.S., F.v.P., H.M.H., S.K., F.R., K.A.K., G.K., N.M., E.B., C.M., L.M.W., J.P.Z., B.G., J.C., D.B., I.I., L.K., A.B. and S.S.B. wrote the paper, discussed the results and contributed to the final manuscript. All authors have read and approve the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}